Reimbursement Policy for Biosimilars Will Have Negative Consequences for Patients

Tara O’Neill of the American Action Forum argues that the decision over how biosimilars should be reimbursed by the Centers for Medicare & Medicaid Services (CMS) should be determined by economic principles based on the value of the medication to patients and without putting patient safety and access to such products at risk. If the statutory text does not clearly provide for the favorable regulatory outcome of these factors, it should be amended.